Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
Identify your ideal budgeting method by evaluating spending habits, goals, and flexibility. A straightforward guide to choosing wisely.
22,123 articlesAs large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
Lawmakers unveil a plan centered on a common-sense approach housing affordability to address supply and cost hurdles....
Opendoor expands its cash-offer toolkit through a RealScout integration, framing it as opendoor’s ‘grand reopening’: ...
When great growth ideas stumble, the long-term case often remains intact. This piece examines two names that have fal...
Hongkong Land is reinventing itself after more than a century, shifting from Hong Kong-centric rents to a broader Asi...
The AI-fueled rally pushes major indices higher, yet a tightening macro backdrop and tougher oversight loom as the ma...
Accenture says it will hire more entry-level graduates this year than last, citing a need to onboard Gen Z workers wh...
The federal budget deficit projected to approach $2 trillion this fiscal year signals a turning point for U.S. borrow...
Vice President JD Vance publicly pushed back on questions about President Trump's stock trading, arguing that the bil...
A biotech powerhouse is drawing fresh attention as Moderna slows, delivering stronger cash flow, patent extensions, a...
Star Bulk reported a solid Q1 2026, reflecting steady demand for commodities and a modern fleet. This article unpacks...
Syndicate Labs, a16z-backed, is closing its development arm after five years of building on-chain tooling, blaming a ...